Fibromyalgia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Fibromyalgia

Fibromyalgia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Fibromyalgia is a syndrome characterized by chronic widespread pain at multiple tender points, joint stiffness, and systemic symptoms (e.g., mood disorders, fatigue, cognitive dysfunction, and insomnia) [1–4] without a well-defined underlying organic disease.

Fibromyalgia classification based on the triggers:

Cervical pathology.
Metabolic/endocrine conditions.
Inflammatory/autoimmune conditions.
Peripheral/central nervous system conditions.
Mixed

Epidemiology-

According to systematic literature survey and Thelansis disease modeling data Fibromyalgia disorder affects an estimated 10 million people in the U.S. and an estimated 3-6% of the world population. While it is most prevalent in women. 75-90 percent of the people who have FM are women.

Competitive landscape of Fibromyalgia includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Fibromyalgia across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Fibromyalgia Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Fibromyalgia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 NYX-2925 Aptinyx Phase 2
2 ASP0819 Astellas Pharma Inc Phase 2
3 TD-9855 Group 1 Theravance Biopharma Phase 2
4 TNX-102 SL Tonix Pharmaceuticals, Inc. Phase 3
5 INC-1 Virios Therapeutics, Inc. Phase 2
6 Duloxetine Eli Lilly and Company Phase 3
7 [S,S]-Reboxetine Pfizer Phase 3
8 Fremanezumab - Dose A Teva Branded Pharmaceutical Phase 2
9 Device: AVACEN Thermal Exchange System Avacen, Inc. Phase 2
10 DS-5565 Syneos Health Phase 3
11 DS-5565 Daiichi Sankyo, Inc. Phase 3
12 Pregabalin Release Tablets Jiangsu HengRui Medicine Co., Ltd. Phase 3
13 GRT9906 Grünenthal GmbH Phase 2
14 ropinirole GlaxoSmithKline Phase 2
15 Lacosamide UCB Pharma Phase 2
16 KL16-012 Knop Laboratorios Phase 2
17 Injectafer American Regent, Inc. Phase 2
18 Botulinum toxin type A Ipsen Phase 2
19 Botulinum toxin type A Allergan Phase 3
20 Ibuprofen Spherium Biomed Phase 2
21 Erenumab-aooe (EREN) Novartis Pharmaceuticals Phase 2